Form 4 for ACRS Aclaris Therapeutics, Inc.
Accepted 2024-03-05 00:00:00 ET · period of report 2024-03-01 · accession 0001209191-24-004397 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-03-05 | 2024-03-01+ | ACRS | Balthaser Kevin | CFO | M - OptEx | — | +4,975 | 24.4K | +26% | — |
| DM | 2024-03-05 | 2024-03-01+ | ACRS | Balthaser Kevin | CFO | F - Tax | $1.24 | -1,417 | 24.0K | -6% | -$1,757 |
| DM | 2024-03-05 | 2024-03-01+ | ACRS | Balthaser Kevin | CFO | M - OptEx | $0.00 | -4,975 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-01 | M | A | 1,100 | — | 21,525 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| 2 | Common | Common Stock | 2024-03-01 | F | D | 313 | $1.24 | 21,212 | D | — | — | |
| 3 | Common | Common Stock | 2024-03-01 | M | A | 2,375 | — | 23,587 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| 4 | Common | Common Stock | 2024-03-01 | F | D | 677 | $1.24 | 22,910 | D | — | — | |
| 5 | Common | Common Stock | 2024-03-02 | M | A | 1,500 | — | 24,410 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| 6 | Common | Common Stock | 2024-03-02 | F | D | 427 | $1.24 | 23,983 | D | — | — | |
| 7 | Derivative | Restricted Stock Units | 2024-03-01 | M | D | 1,100 | $0.00 | 1,100 | D | — · — to — | 1,100 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F3) The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. |
| 8 | Derivative | Restricted Stock Units | 2024-03-01 | M | D | 2,375 | $0.00 | 4,750 | D | — · — to — | 2,375 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F4) The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date. |
| 9 | Derivative | Restricted Stock Units | 2024-03-02 | M | D | 1,500 | $0.00 | 0 | D | — · — to — | 1,500 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F5) The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of March 2, 2023 and March 2, 2024, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. |